The results of the study of the effectiveness and safety of the use of Mexidol in patients with chronic brain ischemia

Author:
E.I. Chukanova, A.S. Chukanova, H.I. Mamaeva

GBOU VPO “Russian National Research Medical University named after N.I. Pirogov ", Moscow

Place of publication:
JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2, 2015

Abstract:
Objective of the study. To analyze the efficacy and safety of Mexidol and its impact on the dynamics of neurological manifestations of the disease, emotional status, and quality of life in patients with chronic cerebral ischemia (CCI). Material and methods. Forty-five patients with CCI were observed; they received Mexidol 500 mg intravenously by drip once a day for 14 days, followed by oral administration of 500 mg (2 tablets 2 times a day) for 60 days. The comparison group consisted of 30 patients with CCI, matched for age, the presence of risk factors, and the severity of neurological manifestations, who did not take Mexidol. Patients in both groups received background therapy, including drugs to achieve complete correction of their existing risk factors. The state of cognitive functions (MMSE questionnaire), motor activity, and quality of life parameters (SF-36) were assessed. Results. By the end of the study (day 74), patients in the main group, compared with those in the comparison group, demonstrated a significant reduction in the severity of motor impairments, a normalization of the SF-36 utility score, and a significant improvement in the mean scores of the Multidimensional Cognitive Assessment (MMSE). Analysis of the study results confirmed the high efficacy and safety of Mexidol in treating patients with chronic myocardial infarction.